The U.S. Preventive Services Task Force (USPSTF) has identified a number of research questions around PrEP that focus on the efficacy of risk assessment tools and new PrEP regimens like injectable cabotegravir. Follow-up recommendations will be issued by USPSTF, and those receiving a A or B rating will be covered by most insurance plans with no cost sharing.
A recent HIV.gov blog, USPSTF Publishes Research Plan for Review of PrEP Recommendation, outlines the process followed in examining these questions. USPFSTF's website presents the Final Research Plan: Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis, published January 13, 2022.